Cargando…
Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT
Some antihypertensive drugs have also renoprotective and anti-inflammatory properties that go beyond their effect on blood pressure. It has been suggested that microalbuminuria and glomerular filtration rate (GFR) are associated with circulating levels of the soluble form of the receptor, sRAGE (sol...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306936/ https://www.ncbi.nlm.nih.gov/pubmed/22474401 http://dx.doi.org/10.1155/2012/874149 |
_version_ | 1782227257451872256 |
---|---|
author | Falcone, Colomba Buzzi, Maria Paola Bozzini, Sara Boiocchi, Chiara D'Angelo, Angela Schirinzi, Sandra Esposito, Ciro Torreggiani, Massimo Choi, Jasmine Ochan Kilama, Michael Mancia, Giuseppe |
author_facet | Falcone, Colomba Buzzi, Maria Paola Bozzini, Sara Boiocchi, Chiara D'Angelo, Angela Schirinzi, Sandra Esposito, Ciro Torreggiani, Massimo Choi, Jasmine Ochan Kilama, Michael Mancia, Giuseppe |
author_sort | Falcone, Colomba |
collection | PubMed |
description | Some antihypertensive drugs have also renoprotective and anti-inflammatory properties that go beyond their effect on blood pressure. It has been suggested that microalbuminuria and glomerular filtration rate (GFR) are associated with circulating levels of the soluble form of the receptor, sRAGE (soluble receptor for advanced glycation ends-products). In the present analysis, we used data from the TALENT study to evaluate soluble receptor for advanced glycation end-products (sRAGE) plasma levels in patients with hypertension and high-cardiovascular risk-treated nifedipine and telmisartan in combination. Treatment with nifedipine-telmisartan significantly decreased mean systolic and diastolic ambulatory blood pressure and resulted in a significant increase in sRAGE plasma concentrations after 24 weeks of therapy. We concluded that in hypertensive patients with early-stage renal disease, sRAGE concentrations are not influenced by either microalbuminuria or GFR. Long-term treatment with a combination of nifedipine-telmisartan may have a beneficial effect increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-inflammatory activity. |
format | Online Article Text |
id | pubmed-3306936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33069362012-04-03 Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT Falcone, Colomba Buzzi, Maria Paola Bozzini, Sara Boiocchi, Chiara D'Angelo, Angela Schirinzi, Sandra Esposito, Ciro Torreggiani, Massimo Choi, Jasmine Ochan Kilama, Michael Mancia, Giuseppe Mediators Inflamm Research Article Some antihypertensive drugs have also renoprotective and anti-inflammatory properties that go beyond their effect on blood pressure. It has been suggested that microalbuminuria and glomerular filtration rate (GFR) are associated with circulating levels of the soluble form of the receptor, sRAGE (soluble receptor for advanced glycation ends-products). In the present analysis, we used data from the TALENT study to evaluate soluble receptor for advanced glycation end-products (sRAGE) plasma levels in patients with hypertension and high-cardiovascular risk-treated nifedipine and telmisartan in combination. Treatment with nifedipine-telmisartan significantly decreased mean systolic and diastolic ambulatory blood pressure and resulted in a significant increase in sRAGE plasma concentrations after 24 weeks of therapy. We concluded that in hypertensive patients with early-stage renal disease, sRAGE concentrations are not influenced by either microalbuminuria or GFR. Long-term treatment with a combination of nifedipine-telmisartan may have a beneficial effect increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-inflammatory activity. Hindawi Publishing Corporation 2012 2012-02-13 /pmc/articles/PMC3306936/ /pubmed/22474401 http://dx.doi.org/10.1155/2012/874149 Text en Copyright © 2012 Colomba Falcone et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Falcone, Colomba Buzzi, Maria Paola Bozzini, Sara Boiocchi, Chiara D'Angelo, Angela Schirinzi, Sandra Esposito, Ciro Torreggiani, Massimo Choi, Jasmine Ochan Kilama, Michael Mancia, Giuseppe Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT |
title | Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT |
title_full | Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT |
title_fullStr | Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT |
title_full_unstemmed | Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT |
title_short | Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT |
title_sort | microalbuminuria and srage in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of talent |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306936/ https://www.ncbi.nlm.nih.gov/pubmed/22474401 http://dx.doi.org/10.1155/2012/874149 |
work_keys_str_mv | AT falconecolomba microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent AT buzzimariapaola microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent AT bozzinisara microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent AT boiocchichiara microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent AT dangeloangela microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent AT schirinzisandra microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent AT espositociro microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent AT torreggianimassimo microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent AT choijasmine microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent AT ochankilamamichael microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent AT manciagiuseppe microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent |